Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Diffuse large B cell lymphoma in Brazil: Understanding the patient journey to improve healthcare assistance.

Thais Fischer, Guilherme Duffles, Lays Leonel et al. Nov 03, 2025 pp. 1894-1894 10.1182/blood-2025-1894

Abstract Background Diffuse Large B-cell Lymphoma not otherwise specified (DLBCL-NOS) is the most common type of non-Hodgkin lymphoma (NHL)....

Real-world outcomes of venetoclax-based therapy vs intensive chemotherapy in older adults with newly diagnosed Acute Myeloid Leukemia

Ali Sanjari Moghaddam, Hannah Ruby, Ameera Syed et al. Nov 03, 2025 pp. 6996-6996 10.1182/blood-2025-6996

Abstract Title: Real-World Outcomes of Venetoclax-Based Therapy vs Intensive Chemotherapy in Older Adults With Newly Diagnosed Acute Myeloid...

Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial

Kelly Bolton, Yazan Madanat, Namrata Chandhok et al. Nov 03, 2025 pp. 635-635 10.1182/blood-2025-635

Abstract BACKGROUND Ivosidenib is an oral inhibitor of mutant isocitrate dehydrogenase type I (IDH1) currently approved for the treatment of...

Artificial intelligence system for delivering interactive and verifiable guideline-based clinical decision support in hematology

Jiasheng Wang, Kirti Arora, David Swoboda et al. Nov 03, 2025 pp. 2578-2578 10.1182/blood-2025-2578

Abstract Background: Artificial Intelligence (AI) has shown great potential in enhancing clinical practice. Many medical societies, includin...

SLC7A11 suppresses ferroptosis via arginine metabolism and promotes tumor immune escape in acute lymphoblastic leukemia

Jianda Hu, Jiazheng Li, Qing Cai et al. Nov 03, 2025 pp. 1483-1483 10.1182/blood-2025-1483

Abstract Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by high heterogeneity. Despite advancements in treatme...

Biophysical characterization of red blood cells in sickle cell trait reveals heterogeneous and intermediate pathophysiological profiles

Zoe Sekyonda, Payam Fadaei, Yuxuan Du et al. Nov 03, 2025 pp. 1156-1156 10.1182/blood-2025-1156

Abstract Introduction: Sickle hemoglobin (HbS) results from a single nucleotide substitution in the β-globin gene. Individuals with homozygo...

Neonatal platelets induce monocytes to a myeloid derived suppressor cell phenotype

Preeti Maurya, James Palis, Craig Morrell Nov 03, 2025 pp. 420-420 10.1182/blood-2025-420

Abstract Work by our lab and others have shown that compared to neonatal platelets, adult platelets are relatively enriched in both transcri...

Real-world vs. clinical trial data of belantamab mafodotin's ocular toxicities: A comparative analysis

Sejal Murthy, Sneha Purvey, Bharadhwaj Kolipakkam et al. Nov 03, 2025 pp. 7587-7587 10.1182/blood-2025-7587

Abstract Introduction: Belantamab mafodotin is an antibody-drug conjugate (ADC) that is used for treatment of relapsed/refractory Multiple M...

From mechanistic synergy to clinical breakthrough: Updated results from a phase II Trial of HD-MTX, selinexor, and zanubrutinib in CNS lymphoma

Li Li, Bing Pan, Kaiyi Liu et al. Nov 03, 2025 pp. 3550-3550 10.1182/blood-2025-3550

Abstract Background: Central nervous system lymphoma(CNSL) is an aggressive extranodal non-Hodgkin lymphoma, most commonly classified as diff...

Oral iptacopan demonstrates efficacy as salvage therapy for high-risk transplant-associated thrombotic microangiopathy: First real-world experience

Fei Gao, Qi Wen, Jian-Ping Zhang et al. Nov 03, 2025 pp. 2431-2431 10.1182/blood-2025-2431

Abstract Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is a life-threatening complication after hematopoietic stem c...

Mosunetuzumab in combination with zanubrutinib is safe in patients with relapsed/refractory follicular lymphoma: Safety run-in results from the FIL-mozart Phase II study

Rita Tavarozzi, Marco Ladetto, Francesca Bonello et al. Nov 03, 2025 pp. 7096-7096 10.1182/blood-2025-7096

Abstract Introduction Treatment of relapsed/refractory (R/R) follicular lymphoma (FL) is shifting toward chemo-free regi...

Budget impact analysis for sickle cell disease point-of-care testing in Mozambique

La'Ron Browne, Nancy Bolous, Rocio Caja Rivera et al. Nov 03, 2025 pp. 4369-4369 10.1182/blood-2025-4369

Abstract Background: Sickle cell disease (SCD) is a leading cause of under-five mortality and morbidity in Sub-Saharan Africa. Effective neo...

Reassessing pre-chemotherapy laboratory testing in R-CHOP: Are we doing too much?

Mohamed Warsame, Bolun Liu, Hadiyah Audil et al. Nov 03, 2025 pp. 6188-6188 10.1182/blood-2025-6188

Abstract Background: Routine laboratory testing prior to chemotherapy administration is a cornerstone of hematology and oncology practice, a...

Building a kenyan framework for advanced multiple myeloma care: Outcomes from the 2024 national workshop

Beatrice Jepngetich, Kevin Manyega, evangeline Njiru et al. Nov 03, 2025 pp. 2643-2643 10.1182/blood-2025-2643

Abstract Background: Kenya faces significant gaps in multiple myeloma (MM) management, with available data (likely underreported) indicating...

Epidemiology and clinical characteristics of idiopathic multicentric castleman disease in Spain (ARCANA study): Prevalence cohort

Jose Tomas Navarro, Ana Jiménez Ubieto, Araceli Rubio Martinez et al. Nov 03, 2025 pp. 3006-3006 10.1182/blood-2025-3006

Abstract Background Idiopathic multicentric Castleman disease (iMCD) is a rare, heterogeneous lymphoproliferative disorder affecting multipl...

Variances in patient reported experiences with shared decision-making by biological sex in patients with diffuse large B-cell lymphoma (DLBCL) – an analysis from the lymphoma coalition 2024 global patient survey on lymphomas and CLL

Lorna Warwick, Shawn Sajkowski, Natacha Bolanos Nov 03, 2025 pp. 2765-2765 10.1182/blood-2025-2765

Abstract Introduction Shared decision-making (SDM) remains a key aspect of the patient-centred care paradigm in patients with lymphomas and...

RESHAPE: A non-interventional study of real-world treatment patterns and outcomes across age groups in people with severe hemophilia A in Latin America, Eastern Europe, Africa, Asia, and the Middle East

Felipe Lemos García, Max Zortel, Alexander Demyanov et al. Nov 03, 2025 pp. 3062-3062 10.1182/blood-2025-3062

Abstract Background: Detailed treatment outcomes data in people with congenital hemophilia A (PwHA) outside North America, Western Europe, a...

Impact of obesity on survival outcomes in Acute Myeloid Leukemia patients treated with hypomethylating agents: A retrospective multicenter cohort study using real-world data

Teja Sureddi, Abdallah Hussein, Eric Osgood et al. Nov 03, 2025 pp. 1615-1615 10.1182/blood-2025-1615

Abstract Background Obesity is a growing global health concern and has been associated with worse outcomes in various malignancies. However,...

Low-dose chemotherapy for induction in pediatric AML: Retrospective outcome analysis across expanded cohorts

Li Gao, Xiaowen Zhai, Ningling Wang et al. Nov 03, 2025 pp. 1661-1661 10.1182/blood-2025-1661

Abstract Background: Our phase 3 randomized trial (CALSIII-AML18; n = 497) previously demonstrated non-inferior complete remission (CR/CRi)...

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Magdalena Corona De Lapuerta, Maria Sanchez-Tabernero, Alejandro Medina et al. Nov 03, 2025 pp. 922-922 10.1182/blood-2025-922

Abstract Introduction: Current identification of high-risk Multiple Myeloma (HRMM) primarily relies on the Revised International Staging Sys...

Machine-learning-augmented prediction of tumor metabolic burden and survival in multiple myeloma using clinical indicators

Jingwen Zhang, Xiaoyan Lv, Qingbin Wang et al. Nov 03, 2025 pp. 4003-4003 10.1182/blood-2025-4003

Abstract Background:PET-CT is a powerful imaging tool that can provide a detailed display of the lesion distribution, quantity, size and met...

Successful fertility preservation during curative therapy in female adolescent sickle cell anemia patients

Stacey Rifkin-Zenenberg, Laurie Donnelly, Elana Smilow et al. Nov 03, 2025 pp. 6531-6531 10.1182/blood-2025-6531

Abstract Introduction: Sickle cell anemia (SCA) is a life limiting disease characterized by vasoocclusive episodes. Pati...

Transfusion independence in thalassemia patients after failure of gene therapy or with hemoglobin h constant spring and hb e using luspatercept: A case series

Grace Chandler, Stephanie Matthies, Sherif Badawy Nov 03, 2025 pp. 2921-2921 10.1182/blood-2025-2921

Abstract Background: Individuals with thalassemia who depend on blood transfusions to maintain adequate hemoglobin levels are at high risk o...

Long term outcomes of ET and PV patients after clinical trial treatment with interferon alfa

Megan Metzger, Heidi Kosiorek, Ashley Yu et al. Nov 03, 2025 pp. 7345-7345 10.1182/blood-2025-7345

Abstract Background Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms (...

Hematologic neoplasms and hypertension: National trends and associations in the United States, 1999–2023 — a CDC wonder analysis

Nafila Zeeshan, Sravani Bhavanam, Nayanika Tummala et al. Nov 03, 2025 pp. 8200-8200 10.1182/blood-2025-8200

Abstract Background: Hypertension is a major contributor to cardiovascular disease and a common comorbidity in patients with hematological c...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page